linjc16/ctgov huggingface dataset:
Role of MSCT of Chest in Differentiation Between COPD Patients According to Their Smoking Status

Study Overview
=================
Brief Summary
-----------------
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality all over the world. Smoking is considered as an important risk factor, but other risk factors are present. Around 30 % of patients with COPD are non-smokers. Cessation of smoking in patients with COPD causes decreases the presence of micronodules and other criteria of CT chest. In last few years, some researchers reported that cessation of smoking raise the apparent extent of emphysema. The cause is not obvious, but this paradoxical fall in lung density is thaught to be resulting from decrease in inflammation after smoking cessation. CT chest criteria of COPD in active smokers, non-smokers and ex-smokers seem to be different. So, comparison between CT chest Criteria of COPD in smokers, ex-smokers and non-smokers will be searched in this study to detect the role of multislice computed tomography (MSCT) chest in differentiation between COPD patients according to their smoking status.

Detailed Description
-----------------
Basic ethical principles of medical research; beneficence (do well), non-maleficence (do no harm), respect and distributive justice were implemented. The study will be carried out in accordance with the Declaration of Helsinki and the principles of good clinical practice.

Official Title
-----------------
Role of Multislice Computed Tomography (MSCT) Chest in Differentiation Between Chronic Obstructive Pulmonary Disease(COPD) Patients According to Their Smoking Status

Conditions
-----------------
Patient Participation

Intervention / Treatment
-----------------
* Diagnostic Test: MSCT chest


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with chronic obstructive Pulmonary Disease. Patients above 18 years. Exclusion Criteria: Patients with unclear smoking history. Patients with active pneumonia. Patients with acute COPD exacerbation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| First Group<br>Thirty patients of COPD smokers patients. | Diagnostic Test: MSCT chest<br>* Multi slice Computed Tomography of the chest<br>|
| Second group<br>Thirty patients of COPD ex-smokers patients. | Diagnostic Test: MSCT chest<br>* Multi slice Computed Tomography of the chest<br>|
| Third group<br>Thirty patients of COPD non-smokers patients. | Diagnostic Test: MSCT chest<br>* Multi slice Computed Tomography of the chest<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with criteria of severe COPD | Criteria of severe COPD include emphysematous bullae, thick bronchial walls. | 18 months |
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.

Detailed Description
-----------------
Treatment medication will be administered topically twice daily for 28 days

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Drug: Product 0405
* Drug: Placebo for Product 0405


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Atopic Dermatitis Good health with the exception of Atopic Dermatitis Percent body surface area minimum requirements Exclusion Criteria: Subjects who are pregnant, nursing or planning a pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Product 0405<br>Topical active investigational Product 0405 | Drug: Product 0405<br>* Product 0405 will be administered topically twice daily for 28 days<br>|
| Placebo Comparator: Placebo for Product 0405<br>Topical Placebo for Product 0405 | Drug: Placebo for Product 0405<br>* Placebo for Product 0405 will be administered topically twice daily for 28 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Statistically significant superiority of the test Product 0405 to the vehicle |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of success based on the Investigators Static Global Assessment and the Clinical Signs and Symptoms (erythema, scaling) at the end of treatment. |  | 28 days |
TMTP1 Targeting Micro-metastasis LN in Laparoscopic SLN Detection in Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
Investigators aimed to determine the validity of the investigator's novel tumor targeted fluorescent peptide TMTP1-ICG to increased accuracy of laparoscopic SLN mapping

Official Title
-----------------
Novel Tumor Targeted Fluorescent Peptide TMTP1-ICG Mapping in Laparoscopic Sentinel Micro-metastasis Lymph Node Detection in Cervical Cancer Patients

Conditions
-----------------
Cervical Cancer, Sentinel Lymph Node

Intervention / Treatment
-----------------
* Procedure: ICG
* Procedure: ICG-CP
* Procedure: ICG-TMTP1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Without childbearing requirements at the time of consent. FIGO stage IB1, IIA1 cervical cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan. Subject has provided written informed consent. Exclusion Criteria: Breast-feeding or pregnant. Ongoing participation in another clinical trial with an investigational drug with 3 months Own allergy towards ICG and/or alcohol Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ICG<br> | Procedure: ICG<br>* The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.<br>|
| Active Comparator: ICG-CP<br>CP, control peptide | Procedure: ICG-CP<br>* The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.<br>|
| Experimental: ICG-TMTP1<br>also named as TMTP1-ICG | Procedure: ICG-TMTP1<br>* The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection rate of micro-metastasis sentinel lymph node | Detection of micro-metastasis sentinel lymph node per patient | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity | Sensitivity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG or ICG-CP | 7 days | 
| Specificity | Specificity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG or ICG-CP | 7 days | 
| Incidence of adverse events |  | 7 days |
Socket Shield vs Conventional Immediate Implant

Study Overview
=================
Brief Summary
-----------------
eighteen implants will be placed in patients with non-restorable maxillary teeth in the aesthetic area.the recruited patients will be divided into two groups .group 1 will undergo socket shield technique with immediate temporization ,while group 2 will undergo conventional immediate implant placement with immediate temporization. to compare bone loss and aesthetic outcomes in the two techniques.

Official Title
-----------------
Esthetic Zone Socket Shield Technique With Immediate Temporization vs. Conventional Immediate Implant Placement With Immediate Temporization Randomized Clinical Trial

Conditions
-----------------
Preservation of the Labial Bone

Intervention / Treatment
-----------------
* Procedure: socket shield technique
* Procedure: conventional immediate implant placement with immediate temporization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with non-restorable maxillary anterior teeth in the esthetic zone indicated for implant placement. Both sexes. No intraoral soft and hard tissue pathology No systemic condition that contraindicate implant placement Exclusion Criteria: Heavy smokers more than 20 cigarettes per day. Patients with systemic disease that may affect normal healing. Psychiatric problems Disorders to implant are related to history of radiation therapy to the head and neck neoplasia

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: socket shield technique<br>socket shield technique with immediate temporization | Procedure: socket shield technique<br>* socket shield technique with immediate temporization<br>|
| Active Comparator: conventional immediate implant<br>conventional implant placement with immediate temporization | Procedure: conventional immediate implant placement with immediate temporization<br>* conventional immediate implant placement with immediate temporization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implant stability | implant stability will be measured using osstell device | immediately after implant placement | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of bone loss | Will be measured using linear measurements from CBCT | after 3 month from implant insertion. |
Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Study Overview
=================
Brief Summary
-----------------
we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Detailed Description
-----------------
we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in enhancing chloroquine effect.

Official Title
-----------------
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?

Conditions
-----------------
COVID

Intervention / Treatment
-----------------
* Drug: Chloroquine or hydroxychloroquine
* Drug: zinc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with positive COVID-19. Exclusion Criteria: Contraindications or hypersensitivity to chloroquine.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chloroquine or hydroxychloroquine<br>Chloroquine or hydroxychloroquine alone | Drug: Chloroquine or hydroxychloroquine<br>* Chloroquine or hydroxychloroquine<br>* Other names: alexoquine, chloroquine, hydroquine;|
| Experimental: Chloroquine or hydroxychloroquine with zinc<br>Chloroquine or hydroxychloroquine with zinc | Drug: Chloroquine or hydroxychloroquine<br>* Chloroquine or hydroxychloroquine<br>* Other names: alexoquine, chloroquine, hydroquine;Drug: zinc<br>* Zinc tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with improvement or mortality | The number of patients with improvement or mortality. | 2 weeks |
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
To evaluate safety and efficacy of MD-15 intraocular lens implanted into the aphakic eyes

Official Title
-----------------
Open Label, Phase/3 Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: MD-15 Intraocular Lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who intend to undergo phacoemulsification cataract extraction Exclusion Criteria: Patients who undergo secondary implantation Patients with vision loss induced by causes other than cataract Patients who the principal investigator/subinvestigator considers ineligible for enrollment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MD-15<br>Investigational intraocular lens | Device: MD-15 Intraocular Lens<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corrected visual acuity |  | Week 52 |
Computational Imaging Research Based on Deep Learning

Study Overview
=================
Brief Summary
-----------------
Computational imaging research based on deep learning

Detailed Description
-----------------
Based on the current technical challenges, subject development and upgrade of knowledge, to avoid the occurrence of adverse medical accidents, simplify the diagnostic process, artificial intelligence has become the alternative method of choice, by constructing training deep learning model, the CTA as model inputs aneurysm detection and diagnosis to improve diagnosis effectiveness, promote the development of medical technology

Official Title
-----------------
Computational Imaging Using Pixel-level Graph Adversarial Learning

Conditions
-----------------
Arterial Aneurysm

Intervention / Treatment
-----------------
* Diagnostic Test: Aneurysm diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18-80 years. CT paired imaging data of vessels, including layer-to-layer plain CT and enhanced CT. 2 Time range: January 2010 to December 2021. Scanning sites: CT and CTA of head, neck, chest, abdomen or iliac. Exclusion Criteria: Unpaired CT image . Severe artifact CT image. enhancement CT failure image (failure to capture arterial phase or poor arterial development, insufficient flow of contrast agent, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Aneurysm diagnosis|Intelligent detection and diagnosis of aneurysm diagnosis by CTA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective evaluation | using SSIM\MAE index evaluation | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arterial Aneurysm
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases

Study Overview
=================
Brief Summary
-----------------
Recent data have shown that the inadequate vitamin D status plays a role in the manifestation of the haematologic tumors and serum vitamin D level has a prognostic role also as it determines the tumor mortality. But data have not proved a causal relationship between the inadequate vitamin D status and the unfavourable outcomes so far. It is also still unknown, whether the normalization of vitamin D status in patient with vitamin D inadequacy is able to improve the prognosis and survival. In this study the investigators examine the role of the adequate vitamin D substitution in the improvement of the outcomes of haematologic disorders.

Official Title
-----------------
Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases

Conditions
-----------------
Chronic Lymphoid Leukemia

Intervention / Treatment
-----------------
* Drug: Cholecalciferol
* Drug: oleum neutralicum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years old male or female chronic lymphoid leukaemia, any Rai stage 25-OH-Vitamin-D3 level between 10 and 30 ng/mL Exclusion Criteria: serum calcium > 2,60 mmol/l 24 hour calcium urine excretion > 0,1 mmol/kg/day serum phosphate > 1,45 mmol/l eGFR < 30 ml/min/1,73m2 nephrolithiasis receiving parenteral vitamin-D3 in past 6 months activated vitamin-D3 treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>no treatment | Drug: oleum neutralicum<br>* Placebo comparator, 9 ml monthly<br>|
| Active Comparator: Cholecalcipherol<br>Treatment with 180 000 IU cholecalcipherol monthly | Drug: Cholecalciferol<br>* 180.000 IU monthly<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to treatment needed |  | up to 5 years | 
| Blood lymphocyte count |  | monthly, up to 5 years |
Ultrasonography of Optic Nerve Sheath Diameter for Noninvasive Detection of Raised Intracranial Pressure: ORIENT Study

Study Overview
=================
Brief Summary
-----------------
This study aims to adopt a multi-center large sample size study to define (1) the normal range of Chinese ONSD; (2) ONSD diagnosis for patients with high intracranial pressure; (3) to analyze the correlation between ONSD and intracranial pressure.

Detailed Description
-----------------
The ONSD, transcranial Doppler parameters and baseline data of the normal intracranial pressure group and the enhanced intracranial pressure group (more than 200 mmH2O) .

Official Title
-----------------
Ultrasonography of Optic Nerve Sheath Diameter for Noninvasive Detection of Raised Intracranial Pressure: a Chinese Multicenter Study

Conditions
-----------------
Ultrasonography

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People requiring lumbar puncture testing due to brain trauma, intracranial infection, intracranial vascular disease, intracranial tumors, peripheral neuropathy for the raised intracranial pressure group. Healthy people for the normal intracranial pressure group. Exclusion Criteria: eye diseases, such as eye trauma, eye tumors, optic neuritis, and glaucoma People with poor temporal window penetration. Patients who refuse to sign informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| raised intracranial pressure<br>more than 200 mmH2O | Other: no intervention<br>* no intervention<br>|
| the normal intracranial pressure group<br>more than 80 mmH2O and no more than 200 mmH2O | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The normal range of ONSD in healthy Chinese adults. | We will perform ONSD measurements with normal people by using ultrasound. We aim to establish the range for optic nerve sheath diameter (ONSD) in healthy Chinese adults. And the normal range of ONSD will be measured and reported. | 2021.8-2022.8 | 
| determine the ONSD cut-off point for high intracranial pressure. | We will perform ONSD measurements with patients who was suspected high intracranial pressure rand enquiring lumbar puncture. We will analyze the correlation between ONSD and intracranial pressure. And ONSD cut-off point for evaluating high intracranial pressure will be reported. | 2021.8-2022.8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
optic nerve sheath diameter, intracranial pressure